Objective To assess the real-world effectiveness of molnupiravir (MOL) in reducing the need
for hospitalization in at-risk, non-hospitalized patients with confirmed COVID-19. Methods A …

Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …

Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …

Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …

Background The majority of available data on molnupiravir come from an unvaccinated
COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence …

Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …

Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction
in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk …

Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was
introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of …